Lysosomal Storage Disease Market

The global Lysosomal Storage Disease (LSD) market was valued at US$ 7651.9 million in 2022 and is projected to reach US$ 10550 million by 2029, at a CAGR of 4.7% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

The USA market for Global Lysosomal Storage Disease (LSD) market is estimated to increase from USD million in 2022 to reach USD million by 2030, at a CAGR during the forecast period of 2023 through 2030.

The China market for Global Lysosomal Storage Disease (LSD) market is estimated to increase from USD million in 2022 to reach USD million by 2030, at a CAGR during the forecast period of 2023 through 2030.

The Europe market for Global Lysosomal Storage Disease (LSD) market is estimated to increase from USD million in 2022 to reach USD million by 2030, at a CAGR during the forecast period of 2023 through 2030.

Lysosomal Storage Disease (LSD) is a genetic disorder that causes various types of nervous system disorders such as clinical abnormalities and cellular dysfunction. There are more than 65 categories of LSD. This disease can be classified into Lipid Metabolism Disorder and Glycoprotein Metabolism Disorder. Further Lipid Metabolism Disorder is categorized into Gaucher disease & Fabry disease and Glycoprotein Metabolism Disorder into Pompe disease. LSD develops mainly due to deficiency of lysosomal enzyme in the living body. A person suffering from LSD could experience problems like abnormal growth of bones, delay movement of body, deafness, blindness, dementia, respiratory problems, fatigue/weakness, bone & joint deformity, organ enlargement, lung dysfunction, severe & fatal physical & mental health deterioration.

Lysosomal Storage Disease Market aims to provide a comprehensive presentation of the global market for Lysosomal Storage Disease (LSD), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Lysosomal Storage Disease (LSD). Lysosomal Storage Disease Market contains market size and forecasts of Lysosomal Storage Disease (LSD) in global, including the following market information:

• Global Lysosomal Storage Disease (LSD) Market Revenue, 2018-2023, 2024-2030, ($ millions)
• Global top five companies in 2022 (%)

The global LSD market is expected to grow with growing Ashkenazi (Eastern and Western Europe) population, increasing pharmaceutical R&D spending, growing disposable income, rising healthcare expenditure and accelerating economic growth. Key trends of this rare disease market includes progressing drugs under pipeline and increasing preference towards gene therapy. However, there are some factors which can hinder growth of the market including stringent regulations and limited access to patent rights.

We surveyed the Lysosomal Storage Disease (LSD) companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

• Lipid Metabolism Disorder
• Glycoprotein Metabolism Disorder

• Hospitals
• Clinics
• Others

• North America (United States, Canada, Mexico)
• Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe)
• Asia-Pacific (China, India, Japan, South Korea, Australia, Rest of APAC)
• The Middle East and Africa (Middle East, Africa)
• South and Central America (Brazil, Argentina, Rest of SCA)

• Key companies Lysosomal Storage Disease (LSD) revenues in global market, 2018-2023 (estimated), ($ millions)
• Key companies Lysosomal Storage Disease (LSD) revenues share in global market, 2022 (%)

• Actelion Pharmaceuticals
• Amicus Therapeutics
• Arena Pharmaceuticals
• Astellas Pharma
• Astrazeneca
• Biomarin Pharmaceutical
• Eli Lilly
• Lexicon Pharmaceuticals
• Novo Nordisk
• Merck

Outline of Major Chapters:

Chapter 1: Introduces the definition of Lysosomal Storage Disease (LSD), market overview.

Chapter 2: Global Lysosomal Storage Disease (LSD) market size in revenue.

Chapter 3: Detailed analysis of Lysosomal Storage Disease (LSD) company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Lysosomal Storage Disease (LSD) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 8: The main points and conclusions of the report.